Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Minoryx Therapeutics S.L.. (6/14/16). "Press Release: Minoryx Therapeutics appoints Dr. Uwe Meya as Chief Medical Officer". Mataró, Barcelona.

Organisations Organisation Minoryx Therapeutics S.L.
  Group Minoryx (Group)
  Organisation 2 Lupin (Group)
Products Product MIN-102 (Minoryx)
  Product 2 clinical research
Persons Person Meya, Uwe (Minoryx 201606– CMO before Lupin + Synosia + Roche + Novartis + Knoll + Schering)
  Person 2 Martinell, Marc (Minoryx Therapeutics SL 201404 CEO + Co-Founder)
     


Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces the appointment of Dr. Uwe Meya as Chief Medical Officer (CMO).

As a specialist in neurological disorders, Dr. Meya will advance the clinical development of Minoryx’s lead candidate MIN-102 for X-ALD.

Dr. Meya is a neurologist and psychiatrist. He has over 30 years of experience in pharmaceutical research and development, with a special focus on central nervous system (CNS) disorders. He has expertise in all aspects of drug development from first-in-man trials to regulatory filing.

“I am very impressed with Minoryx and the strong science behind its pipeline,” said Dr. Meya. “I am excited to join Minoryx at this very important point in time, to drive clinical studies on orphan diseases with very high unmet medical needs and thus provide relief to patients.”

“We are delighted to welcome Dr. Meya as our CMO,” said Marc Martinell, CEO of Minoryx Therapeutics. “His wealth of expertise in CNS-related research will help us significantly in moving forward the clinical development of our lead candidate MIN-102. He will also support the further development of our pipeline in orphan diseases.”

Minoryx Therapeutics’ MIN-102 is ready to initiate a phase 1 study. It targets the most prevalent peroxisomal disorder, X-linked adrenoleukodystrophy (X-ALD). MIN-102 is a differentiated PPAR gamma agonist with a superior profile for CNS related diseases. It has achieved a robust proof of concept in animal models.

Dr. Meya joins Minoryx Therapeutics from Lupin Atlantis Holdings SA (Zug, Switzerland), where he was responsible for clinical strategy and implementation of studies with new clinical entities in various indications, including neurodegenerative disorders.

Earlier, Dr. Meya led phase 1 and phase 2 clinical studies in neurodegenerative disorders at Synosia Therapeutics (Basel, Switzerland and San Francisco, CA, USA), which was later acquired by Biotie Therapies (Turku, Finland). Prior to this, Dr. Meya was head of research portfolio management as well as serving as clinical research and licensing liaison manager in CNS at Roche (Basel, Switzerland). Before that, Dr. Meya managed a team of researchers in CNS clinical development at Novartis (Basel, Switzerland), having previously held the positions of head of clinical development in CNS at Knoll AG (Ludwigshafen, Germany) and medical advisor/head of clinical psychiatry at Schering AG (Berlin, Germany).

Dr. Meya received his medical degree as well as his doctorate in psychiatry from the University of Aachen (Germany). He is a member of the European College of Neuropsychopharmacology as well as the International Parkinson and Movement Disorder Society and is a founding member of the International College of Geriatric Psychoneuropharmacology.


About MIN-102

MIN-102, Minoryx’s candidate for X-ALD, is in the preclinical stage. It is a differentiated PPAR gamma agonist with a superior profile for CNS related diseases. Minoryx has developed a robust preclinical proof of concept and a comprehensive development plan with early involvement from key opinion leaders. PPAR gamma agonists have shown strong potential in animal models related to the various phenotypes associated with X-ALD. Minoryx’s candidate is the only product in development for potential use across all the main phenotypes. PPAR gamma agonists also show efficacy in multiple models of neurodegenerative diseases, meaning that MIN-102 also offers a significant potential for indication expansion.


About Minoryx Therapeutics

Minoryx is a drug development company specializing in the discovery of new drugs for orphan diseases. The company targets Inborn Errors of Metabolism; a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program is a differentiated PPAR gamma agonist (MIN-102) that has multiple CNS indications. Minoryx harnesses its unique mechanism of action for potential use in X-ALD, a genetic disease characterized by progressive neurologic deterioration with no available pharmacological treatment. Minoryx is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – SEE-Tx.

The Minoryx team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has raised a total of €24M ($26.9M) including €19.4M ($21.7M) Series A in October 2015.

www.minoryx.com


Media and analyst contact:

Andrew Lloyd & Associates
Agnes Stephens | Sandra Régnavaque
agnes@ala.com | sandra@ala.com
@ALA_Group
+ 44 1273 675 100

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Minoryx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top